Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2014-12-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: A structured regimen of NSAIDs (drugs such as ibuprofen or naproxen) during and after ankle fracture surgery will provide adequate pain relief and cause patients to take fewer doses of opioid drugs.
Methods: This will be a prospective, randomized, double-blinded, placebo controlled study of patients with ankle fractures who require surgical treatment by several NSLIJ orthopaedic surgeons at North Shore University Hospital and Long Island Jewish Medical Center. There will be two groups of patients: one getting NSAIDs to take at regularly scheduled times plus a traditional prescription for opioid medication and one receiving the traditional prescription for opioid medication and a placebo. Patients will be assigned to a group from a computer-generated program. Neither the patients nor their doctors or nurses will know what group they are in, only the pharmacist will have that information. Patients in both groups will have the opportunity to take opioid medications if the pain becomes unmanageable. We are evaluating whether patients in the NSAIDs group will a) have no more pain than patients who are prescribed opioid pain killers for the same surgery and b) if the amount of opioid pain killers can be reduced by having patients take scheduled doses of NSAIDs. We will also describe how well or poorly patients heal, looking at several timepoints after surgery, using Xrays to evaluate formation of new bone.
The test (experimental) group will be given a dose of IV (intravenous) ketorolac, which is an NSAID, during surgery, and will be given naproxen 500mg orally two times per day to take on a regular basis after surgery for four weeks. This group will be given percocet 5/325 (an opioid medication) 1-2 pills orally every 4 hours to take as pain medication if the naproxen is not providing adequate pain relief.
The control group will be administered a saline dose during surgery as an equivalent to the IV ketorolac. These patients will take placebo pain pills on a regular basis two times per day for four weeks, and will take percocet for pain relief. This is equivalent to the common pain protocol that is given to patients after ankle fracture surgery, where they are given percocet to be taken on an as-needed basis.
The placebo and naproxen medication will be in unidentifiable capsule form in unmarked bottles. The maximum daily dose of percocet will be 8 pills, so as not to exceed 2.6g acetaminophen daily.
Both groups will take aspirin (ASA) 325mg orally daily for two weeks to prevent blood clots. All patients will take pantoprazole 40mg orally once daily. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the production of stomach acid, to prevent the development of gastrointestinal ulcers.
We will collect demographic data about the patients. We will also collect data about the surgery: surgery time, treating surgeon, type of surgery, location and complexity of fracture.
W are studying the following outcomes: pain relief, opioid use and bone healing. To measure these outcomes, we will use a pain scale called the VAS to look for differences between the group. A change of 10 millimeters on a scale of 100 millimeters will considered to be the important pain difference. We will also ask patients to fill out journals of their medication use, we will perform pill counts, examine Xrays and ask patients to respond to the FFI, a questionnaire to evaluate how well they are functioning.
Patients will be seen for followup at 2 weeks, 6 weeks, 2 months, 6 months, and 1 year after surgery, all but the last visit are the usual and standard visits scheduled after ankle fracture surgery. At each visit, Xrays will be taken of the ankle to evaluate ankle position, and to determine whether bone healing has occurred. Patients will not incur any extra expense as a result of participating in the study.
Since patients will not know which group they have been assigned to -- test (experimental) or control -- the investigators will carefully explain how to determine the need for taking the prescribed opioid pain medication such that patients are not subjected to unnecessary pain. Since both groups will have access to opioid pain medications, the study is designed to determine if those patients in the NSAIDs group already getting the relief from pain will experience pain at lower levels, which we will only be able to determine after the study is completed and the blind is broken.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NSAID cohort
Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
Naproxen
Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
Placebo cohort
Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Naproxen
Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sustained an operative ankle fracture that will be treated at Long Island Jewish Medical Center or North Shore University Hospital
Exclusion Criteria
2. Pregnant women
3. Nursing women
4. Dementia
5. Cognitive compromise requiring legal authorized representative Prisoners
6. Uncontrolled hypertension
7. History of peptic ulcer disease
8. Renal insufficiency
9. History of renal transplant
10. eGFR less than 60 mL/min/1.73 m2
11. Chronic liver disease
12. Blood thinners: vitamin K antagonist, factor Xa inhibitors, heparinoids
13. Chronic steroids
14. Immunosuppressive drugs
15. Inflammatory bowel disease
16. Contraindication/allergy for NSAIDs
17. Positive status for HIV
18. Dixogin
19. Methotrexate
20. Vismodebig
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwell Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ariel T. Goldman, MD
Role: PRINCIPAL_INVESTIGATOR
Northwell Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-391A
Identifier Type: -
Identifier Source: org_study_id